Dr. Evelio H. Sosa, M.D.
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 88
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
FL license ME0069595
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 88
- Services billed
- 188
- Patients’ average age
- 81
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 224 | 72 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 131 | 61 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 101 | 92 |
| Psychiatric diagnostic evaluation with medical services | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Quetiapine Fumarate Other prescribers in Miami, FL | 1,441 |
| Trazodone Hcl Other prescribers in Miami, FL | 1,056 |
| Buspirone Hcl Other prescribers in Miami, FL | 945 |
| Clonazepam Other prescribers in Miami, FL | 745 |
| Escitalopram Oxalate Other prescribers in Miami, FL | 741 |
| Alprazolam Other prescribers in Miami, FL | 649 |
| Sertraline Hcl Other prescribers in Miami, FL | 433 |
| Mirtazapine Other prescribers in Miami, FL | 417 |
| Bupropion Xl (bupropion hcl) Other prescribers in Miami, FL | 370 |
| Temazepam Other prescribers in Miami, FL | 361 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $4,691,205 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Axsome Therapeutics, Inc. - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06025578
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.